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Background: The chaperon heat shock protein 90 (HSP90) constitutes an important target for anti-tumor therapy
due to its essential role in the stabilization of oncogenes. However, HSP90 is ubiquitously active to orchestrate
protein turnover, chemotherapeutics that target HSP90 may affect immune cells as a significant side effect.
Therefore, we asked for potential effects of pharmacological HSP90 inhibition at a therapeutically relevant
concentration on human dendritic cells (DCs) as main inducers of both cellular and humoral immune responses,
and on human CD4+ T cells as directly activated by DCs and essential to confer B cell help.
Methods: Unstimulated human monocyte-derived DCs (MO-DCs) were treated with the prototypical HSP90 inhibitor
geldanamycin (GA). Based on dose titration studies performed to assess cytotoxic effects, GA was applied at a rather
low concentration, comparable to serum levels of clinically used HSP90 inhibitors. The immuno-phenotype (surface
markers, cytokines), migratory capacity, allo T cell stimulatory and polarizing properties (proliferation, cytokine pattern)
of GA-treated MO-DCs were assessed. Moreover, effects of GA on resting and differentially stimulated CD4+ T cells in
terms of cytotoxicity and proliferation were analysed.
Results: GA induced partial activation of unstimulated MO-DCs. In contrast, when coapplied in the course of MO-DC
stimulation, GA prevented the acquisition of a fully mature DC phenotype. Consequently, this MO-DC population
exerted lower allo CD4+ T cell stimulation and cytokine production. Furthermore, GA exerted no cytotoxic effect on
resting T cells, but abrogated proliferation of T cells stimulated by MO-DCs at either state of activation or by stimulatory
antibodies.
Conclusion: HSP90 inhibitors at clinically relevant concentrations may modulate adaptive immune responses both on
the level of DC activation and T cell proliferation. Surprisingly, unstimulated DCs may be partially activated by that
agent. However, due to the potent detrimental effects of HSP90 inhibitors on stimulated CD4+ T cells, as an outcome a
patients T cell responses might be impaired. Therefore, HSP90 inhibitors most probably are not suitable for treatment
in combination with immunotherapeutic approaches aimed to induce DC/T cell activation.
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The ubiquitously expressed chaperon heat shock protein
90 (HSP90), often acting together with other chaperons
like HSP70, binds to a variety of newly synthesized pro-
teins to support their proper folding and to prevent ag-
gregation and interaction with third party proteins [1].
By now, several hundreds of HSP90 client proteins have
been identified, including a number of protooncogenes
[2]. Based on the vital role of HSP90 to stabilize mutated
oncogenic proteins and to promote accumulation of
over-expressed oncogenes [3], and its high level expres-
sion in tumor cells [4], this chaperone has gained long-
standing interest as a molecular target for cancer therapy
[5]. In this regard, the prototypic HSP90 inhibitor gelda-
namycin (GA) exerted strong proapoptotic effects on
tumor cells in vitro [6]. Derivatives of GA [7], and other
HSP90 inhibitors [8], which are optimized in terms of
metabolic stability and reduced hepato-toxicity, are be-
ing tested in several clinical trials [9].
In light of the essential role of HSP90 in protein
homeostasis in all cell types [10], it is of vital importance
to elucidate consequences of drug-mediated inhibition
of HSP90 on the patients’ immune system as required to
eradicate drug-resistant tumor cells [11]. In this respect,
dendritic cells (DCs) as the main inducers of primary
immune responses play an essential role [12]. Stimula-
tion of DCs by pathogen-derived molecular patterns and
endogenous danger signals as well as by activated T cells
results in the activation and upregulated expression of
NF-κB transcription factors like RelB [13], which in turn
orchestrate expression of genes required for functional
DC maturation [14]. Inhibition of HSP90 by GA was
shown to result in diminished NF-κB activity in tumor
cells due to impaired functional activity of NF-κB signal-
ing molecules [15-17]. This suggests a modulatory role
of HSP90 for the DC activation state.
Here we show that treatment of MO-DCs with GA at
low concentration (0.1 μm) resulted in their partial acti-
vation. In contrast, GA interfered with stimulation of
MO-DCs. In addition, GA prevented the proliferation of
stimulated T cells. These findings suggest that inhibition
of HSP90 may differentially affect the DC activation




Peripheral blood mononuclear cells (PBMCs) were derived
from buffy coats of healthy donors by Ficoll density gradi-
ent centrifugation, and monocytes were isolated by plastic
adherence for 1 h in 6-well tissue culture plates (Starlab,
Hamburg, Germany) as described [18]. Monocytes were
differentiated in culture medium (Gibco, Houston, TX),
containing 2% (v/v) heat-inactivated (56°C, 30 min)autologous plasma, penicillin (100 U/ml)/streptomycin
(100 μg/ml) (both PAA, Pasching, Austria), supplemented
with recombinant human (rh) GM-CSF (200 U/ml, Berlex,
Seattle, WA), IL-4 (1,000 U/ml; ImmunoTools, Friesoythe,
Germany). Cells were fed with fresh medium every
other day. On 6 of culture, part of the differentiated
MO-DCs was treated with GA (Alexis Biochemicals,
Lausen, Switzerland) at the concentrations indicated,
and aliquots were stimulated with a cocktail of proin-
flammatory mediators (each 10 ng/ml of rh IL-1β and rh
TNF-α (PeproTech, Hamburg, Germany, and 1 μg/ml
prostaglandin E2 (PGE2, Alexis Biochemicals) for two days
[18,19]. Cell lines HEK293T [20] and IGROV1 [21] were
cultured as described.
Cytotoxicity assays
Cells (MO-DCs: 2×105, HEK293T and IGROV1: 5×104,
CD4+ T cells, prepared as outlined below: 5 × 105) were
seeded into wells of 96-well cell culture plates (Starlab) in
a volume of 100 μl of their respective culture medium,
and GA was added at various concentrations as indicated.
Aliquots of MO-DCs were supplemented with stimulation
cocktail in addition. Two days later, an MTT assay was
performed as recommended by the supplier (Promega,
Madison, WI).
Proliferation assays
CD4+ T cells were enriched from PBMCs by positive
immunomagnetic separation (MACS, Miltenyi Biotec).
CD4+ T cells (105) were cocultured with titrated numbers
of allogenic MO-DCs in 96-well plates (Greiner Bio-One,
Frickenhausen, Germany) in triplicates in 200 μl of culture
medium for 5 days. In some experiments, CD4+ T cells
were stimulated with anti-CD3 (1 μg/ml) plus anti-CD28
(0.5 μg/ml) antibodies (both from BioLegend, San Diego,
CA) for 5 days, in the absence or presence of GA
(0.1 μM). T cell proliferation was assessed by genomic in-
corporation of [3H] thymidine (0.25 μCi/well) added for
the last 16 h of culture, measured in a liquid scintillation
counter (1205 Betaplate, LKB Wallac, Turcu, Finnland).
Cytokine detection
Supernatants of DC cultures were harvested on day 8, and
of DC/T cell cocultures on day 5, and contents of IL-5, IL-
6, IL-12p40, and INF-γ were measured by ELISA as recom-
mended (all ELISA Kits from eBioscience, San Diego, CA).
Flow cytometry
Harvested cells (5×105) were incubated for 20 min at 4°C
with antibodies: fluorescein isothiocyanate (FITC)-conju-
gated anti-HLA-DR (L243), phycoerythrin (PE)-cyanine 5-
conjugated anti-CD80 (2D10), allophycocyanin-conjugated
anti-CD86 (IT2.2) (all from BioLegend), PE-conjugated
anti-CD83 (HB15e; BD Pharmingen, San Diego, CA), and
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washed DCs were analysed in a FACSCalibur (BD Bio-
sciences, Franklin Lakes, NJ) equipped with CELL-
QUEST software (BD). For intracellular detection of
Fascin 1 (Fscn1), MO-DCs were permeabilized with
methanol (10 min on ice), washed with pre-cooled PBS,
and incubated with FITC-conjugated anti-Fscn1 (55 K-2;
Dako, Glostrup, Denmark) or isotype control antibody.
All samples were analysed at the same fluorescence de-
tector settings in order to allow for direct comparison of
mean fluorescence intensities (MFIs).
Migration assays
To prepare 100 μl of DC-loaded collagen matrices, first
5 μl of 7.5% (w/v) Na2CO3 and 10 μl of 10× MEM
(Invitrogen) were mixed, and then added to 75 μl of
PureCol® bovine collagen I (Invitrogen). Afterwards,
67 μl of this mixture was further mixed with 33 μl of
cell suspension containing 3 × 105 DCs, loaded onto a
glass slide covered with a cover slip, and incubated at
37°C for 45 min to allow for gelation. IMDM supple-
mented with penicillin/streptomycin was then added on
top of the collagen gel. Spontaneous migration of MO-
DC populations was monitored for about 6 h in 2 min
intervals by time-lapse microscopy with a BX61 micro-
scope (UAPO lens 20×/340, NA 0.75), equipped with a
FView camera (all Olympus, Hamburg, Germany) using
CellP software (SIS, Münster, Germany).
Promoter reporter assays
HEK293T cells were seeded in wells of a 6 well cluster
plate (Greiner), and were transfected at a confluence of
about 90%. Cells were transfected in parallel with
transcription factor (TF) responsive luciferase reporter
vectors (pAP1-luc, pCRE-luc, pISRE-luc, pNFAT-luc,
pNF-κB-luc, and promoterless negative control; all from
Agilent, Palo Alto, CA). For transfection, plasmid DNA
(4 μg) was complexed with Fugene HD (2 μl; Promega)
for 20 min as recommended by the manufacturer. 5 hr
after transfection, cells were harvested and were equally
split into wells of a 24 well cluster plate (Greiner). On
the following day, triplicates were treated with GA and/
or the MO-DC maturation cocktail. One day later, cells
were harvested, lysed in passive lysis buffer (Promega),
and assayed for luciferase detection in a Turner Designs
TD-20/20 luminometer (Promega). Luciferase activities
were normalized by the activity of the promoterless
reporter.
Western blot analysis
MO-DCs (≥ 1 × 106) were lysed with RIPA buffer (1% (v/v)
NP-40, 1% (v/v) sodium deoxycholate, 0.1% (w/v) SDS,
0.15 M NaCl, 0.01 M Na3PO4, 2 mM EDTA, 1 mM dichlo-
rodiphenyltrichloroethane, 0.2 mM Na3VO4, 50 mM NaF,100 U/ml aprotinin, 1 mM phenylmethylsulfonyl fluor-
ide, and 1% (v/v) of Complete Protease inhibitor cock-
tail (Roche Diagnostics, Mannheim, Germany). Protein
concentrations were quantified by Bradford protein
assay (Bio-Rad, Munich, Germany), and 30 μg of pro-
tein per sample were assayed. Protein samples were
separated on a 10% (w/v) sodium dodecyl sulphate-
polyacrylamide gel, and transferred to a nitrocellulose
membrane (GE Healthcare Europe, Freiburg, Germany).
Western blots were probed with rabbit polyclonal anti-
bodies specific for human p65 NF-κB (C22B4), phospho-
p65 NF-κB (Ser536; 93H1), both from Cell Signaling
Technology (Boston, MA), RelB (C-19; Santa Cruz Bio-
technology, CA), ß-actin (Abcam, Cambridge, UK), and
with mouse anti human monoclonal antibody specific for
IκB-α (L35A5), followed by incubation with a secondary
goat antibody (anti-rabbit or anti-mouse IgG), conjugated
with horseradish peroxidase (all from Cell Signaling Tech-
nology). ECL plus staining (PerkinElmer, Waltham, MA)
served as substrate for horseradish peroxidase.
Statistics
Data are given as mean ± SEM. Statistically significant
differences were analysed by applying the Student’s two-
tailed t test.
Results
GA promotes expression of activation markers by
unstimulated MO-DCs, but interferes with their
stimulation-induced upregulation
Due to the pronounced proapoptotic effect of the
HSP90 inhibitor GA, we first assessed cytotoxicity of this
agent on MO-DCs. As shown in Figure 1a, treatment of
MO-DCs with GA for 48 h resulted in impaired viability
in a dose-dependent manner to a similar extent when
applied to MO-DCs at either unstimulated state or when
coadministered with the stimulation cocktail. Sensitivity
of MO-DCs to the cytotoxic effect of GA was compar-
able to that of the the immortalized cell line HEK293T,
derived from embryonic kidney cells, and IGROV1, an
ovarian adenocarcinoma line (Figure 1b). A concentra-
tion of 0.1 μM GA, which only slightly affected viability
of both MO-DC populations, was used in further
experiments.
Next, we asked for effects of GA on the immuno-
phenotype of MO-DCs. At unstimulated state, treatment
of MO-DCs with 0.1 μM GA resulted in moderately up-
regulated expression of HLA-DR, CD83, and CD86, al-
beit not significant in case of the latter. CD80 surface
expression on the other hand was attenuated (Figure 2a;
Additional file 1: Table S1). In response to treatment with
a stimulation cocktail (IL-1ß, TNF-α, and PGE2), MO-
DCs upregulated expression of either monitored marker
to a significant extent, except for CD80 (Additional file 1:
Figure 1 GA affects the viability of MO-DCs at either state of
activation as well as cancer cells to a similar extent. (a) MO-DCs
on day 6 of culture, and (b) HEK293 and IGROV1 cells were treated
with GA at the concentrations indicated for 48 h in triplicates. One h
after application of GA, aliquots of MO-DCs were stimulated with the
stimulation cocktail (see Methods) in addition. (a, b) Cell viability
was quantified by MTT assay. Viability of untreated cells was arbitrarily
set to 100%. Data represent means ± SEM of two (HEK293), three
(IGROV1), and four (MO-DCs) independent experiments. Statistical sig-
nificance: *versus untreated cells. For reasons of clarity, the degree of
statistical significance is not further delineated (*P < 0.05).
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during stimulation resulted in profound inhibition of all
activation-associated DC surface markers monitored.
MO-DCs at an unstimulated state expressed the pro-
inflammatory cytokines IL-6 and IL-12 at low levels, but
at high extent after stimulation (Figure 2b). GA treat-
ment alone exerted no effect on the production of either
mediator by MO-DCs under basal conditions. However,
when coapplied during stimulation, GA attenuated the
otherwise activation-associated increase of either cyto-
kine. Taken together, these findings suggest that GA dif-
ferentially affects the immuno-phenotype of MO-DCs,
depending on their state of activation.
GA impairs the migratory capacity of MO-DCs
Enhanced migratory activity constitutes another hallmark
of activated DCs. This functional property is regulated in
part by the actin-bundling protein fascin (Fscn)1 [22],which also serves to promote DC/T cell interaction as a
prerequisite for T cell stimulation [23]. Expression of
Fscn1 in unstimulated MO-DCs was slightly reduced after
treatment with GA, and its stimulation-associated upregu-
lation was strongly inhibited in MO-DCs cotreated with
GA during stimulation (Figure 3a). These results sug-
gested detrimental effects of GA on the cytoskeletal plasti-
city of MO-DCs, which in turn may alter their migratory
capacity. To this end, we performed migration assays in
3D collagen gels, intended to mimic the in vivo environ-
ment [24]. Unstimulated MO-DCs were not affected by
GA pretreatment in their spontaneous migration in terms
of distance covered during the time monitored (Figure 3b).
While stimulated MO-DCs were characterized by an en-
hanced mobility, cotreatment with GA during stimulation
resulted in a diminished migratory activity in terms of dis-
tance covered and speed.
The endocytotic capacity, which is characteristic of un-
stimulated DCs, is downregulated upon activation. Un-
stimulated MO-DCs pretreated with GA showed lower
endocytotic uptake of FITC-labeled dextran than un-
treated MO-DCs, albeit not significant (Additional file 2:
Figure S1). This finding is in line with the notion that
GA affects the activation state of unstimulated MO-DCs
to a moderate extent.
GA diminishes the T cell activation capacity of stimulated
MO-DCs
Due to the differential effects of GA on the immuno-
phenotype of unstimulated and stimulated MO-DCs, we
assessed their T cell stimulatory capacity. For this, differ-
entially treated MO-DC populations were cocultured
with allogenic CD4+ T cells, and both T cell proliferation
and the cytokine pattern in DC/T cell cocultures were
analyzed. Unstimulated MO-DCs exerted a moderate allo-
genic T cell stimulatory capacity, while stimulated MO-
DCs mediated strong T cell proliferation (Additional file 3:
Figure S2). Unstimulated MO-DCs pretreated with GA,
in line with partially enhanced expression of activation
markers, elicited slightly higher allogenic T cell prolifer-
ation than untreated MO-DCs. In contrast, MO-DCs
pretreated with the stimulation cocktail plus GA exhib-
ited a significantly impaired allogenic T cell stimulatory
capacity as compared with the corresponding control
(Figure 4a). This finding corresponds with the attenu-
ated expression of activation markers due to interfer-
ence of GA with DC stimulation.
Cocultures that containd untreated MO-DCs were
characterized by low contents of the Th1 marker IFN-γ
and of the Th2 cytokine IL-5, and both cytokines were
present at strongly enhanced levels in DC/T cell cocul-
tures which contained stimulated MO-DCs (Additional
file 3: Figure S2b). Pretreatment of unstimulated and
stimulated MO-DCs with GA resulted in reduced
Figure 2 GA affects the phenotype of MO-DCs in a gene-
dependent manner. Aliquots of MO-DCs on day 6 of culture were
differentially treated with GA (0.1 μM) and/or stimulation cocktail
(see Methods section) as indicated for 48 h. (a) The expression levels
of the markers indicated were assessed by flow cytometry. Upper
panel: Marker expression was detected in unstimulated (−) and
cocktail-stimulated (stim) MO-DCs left untreated (dark line) or treated
with 0.1 μM GA (light grey). Shaded area: isotype control of MO-DCs
left untreated (corresponding isotype controls of GA-treated MO-DCs
were comparable). Graphs are representative of 4-5 independent
experiments each. Lower panel: Relative expression intensities of DC
surface marker expression are given as mean fluorescence intensities
(MFIs), normalized to the MFI of unstimulated or stimulated MO-DCs
left untreated. Data represent the means ± SEM of 4-5 independent
experiments each. (b) Contents of IL-6 and IL-12p40 in the supernatants
of harvested MO-DC populations were assayed by ELISA. Data represent
means ± SEM of 10 independent experiments each. nd: not detectable.
Statistical significance: (a) *versus untreated MO-DCs, (b) *versus
unstimulated untreated MO-DCs, #GA-treated at stimulated versus
unstimulated state. (a, b) *P< 0.05, ##,**P < 0.01, ***P< 0.001.
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compared with the corresponding controls (Figure 4b).
Taken together, so far these results show that GA inter-
feres with the stimulation-induced activation of MO-DCs
in terms of immuno-phenotype, migration, and T cell
stimulatory capacity. In contrast, unstimulated MO-DCs
are partially activated in response to treatment with GA.GA affects distinct signalling pathways, and inhibits
stimulation-induced upregulation of RelB in stimulated
MO-DCs
Next we analysed the outcome of GA-mediated inhib-
ition of HSP90 on the level of transcription factor (TF)
activities as the downstream effectors of cellular signal-
ling. Due to the ubiquitous activity of HSP90, and since
MO-DCs are rather refractory towards non-viral trans-
fection and may be partially activated in response to
transfection [25], we used HEK293T cells for these ana-
lysis. HEK293T cells were transfected with several TF-
responsive luciferase reporter vectors, and rested prior
to treatment with GA and/or the MO-DC stimulation
cocktail, whose components have been shown to stimu-
late this cell line (IL-1ß, and TNF-α [26]; PGE2 [27]).
Under basal conditions, GA treatment exerted either
no (AP1, NFAT) or slightly inhibitory (CREB, STAT1/2)
effects on the TFs monitored (Figure 5a). Only activity
of NF-κB was moderately enhanced by GA. Stimulation
with the maturation cocktail had no effect on NFAT ac-
tivity, but resulted in moderate upregulation of AP1,
STAT1/2, and CREB activity, as well as in pronounced
augmentation of NF-κB activity. Cotreatment with GA
during stimulation had no major effect on the enhanced
activity of CREB and NF-κB, but impaired AP1, and
STAT1/2 activities.
Figure 3 GA impairs the migratory activity of stimulated
MO-DCs. Groups of MO-DCs were generated as described (see legend
of Figure 2). (a) Expression of the actin-bundling protein Fscn1 was
assessed by intracellular flow cytometry. Data represent the means ±
SEM of MFI intensities of 6 independent experiments. (b) Spontaneous
migration of MO-DC populations in 3D collagen matrices was
monitored for 6 h by time lapse analysis in intervals of 2 min. Graphs
represent the means ± SEM of around 80 MO-DCs per group
individually tracked in two independent experiments compiled.
Statistical significance: *versus unstimulated MO-DCs, #GA-treated
MO-DCs at stimulated versus unstimulated state, and $GA-treated
versus untreated MO-DCs at stimulated state (*,$P < 0.05, **P < 0.01,
***,###,$$$P < 0.001).
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ities of distinct TFs at basal conditions, and in response
to stimulation. In light of the well acknowledged import-
ance of NF-κB activity for the DC activation process,
and the finding that GA evoked slightly elevated NF-κB
activation under basal conditions, we asked for effects of
GA on NF-κB regulation in MO-DCs. The ubiquitous
NF-κB family member p65 is upregulated in stimulated
DCs [13,28], and its transient activation is reflected by
phosphorylation of Ser536 [29]. GA treatment exerted
no major effect on the expression level of p65 and the
fraction of phosphorylated protein in unstimulated MO-
DCs (Figure 5b, left panel). Stimulation of MO-DCs re-
sulted in an increase of p65, as reflected by the arisal of
a second band, to a similar extent in both untreated and
GA-treated cells. The fraction of Ser536-phosphorylated
p65 was unaltered, most probably due to the rather long
period of stimulation. We also monitored expression of
the ubiquitously expressed endogenous NF-κB inhibitor
IκB-α, which is degraded immediately after stimulation
of DCs, but strongly upregulated at later time points to
limit NF-κB activation [30]. In line, MO-DCs stimulated
for 48 h, displayed higher IκB-α levels than unstimulated
MO-DCs (Figure 5b, right panel). GA treatment medi-
ated no alterations of IκB-α levels in MO-DCs at either
state of activation. While both p65 and IκB-α are
expressed in a ubiquitous manner, the NF-κB family
member RelB is confined to professional antigen pre-
senting cells (APCs), upregulated in response to stimula-
tion [28]. RelB has proven essential for the acquisition of
a mature DC activation state [31], which prompted us to
monitor its expression. As expected, unstimulated MO-
DCs expressed RelB at low level, which was increased
following stimulation (Figure 5b, right panel). GA treat-
ment of unstimulated MO-DCs yielded a reduced RelB
content as compared with untreated MO-DCs. When ap-
plied in the course of stimulation, GA prevented the other-
wise stimulation-associated increase in RelB expression.
These findings indicate that GA may affect the activ-
ities of a number of TFs. These TFs are known to con-
tribute to determine the state of activity of DCs. In this
Figure 4 GA impairs the T cell activation capacity of stimulated MO-DC. Groups of MO-DCs were generated as described (see legend of
Figure 2). (a) Titrated numbers of the various MO-DC populations (starting at 2 × 104 cells, two-fold diluted) were cocultured with allogenic CD4+
T cells (105) in triplicates for 4 days. T cell proliferation was assessed by uptake of [3H] thymidine during the last 16 h of culture. CD4+ T cell
proliferation as induced by unstimulated or stimulated MO-DCs left untreated employed at the highest DC number was arbitrarily set to one in
each experiment. Graphs show the means ± SEM of 3 independent experiments compiled. (b) Supernatants of day 4 DC/T cell cocultures (ratio
1:5) were assayed for cytokine contents by ELISA. Graphs show relative cytokine levels, normalized to the levels of unstimulated or stimulated
MO-DCs left untreated. Data represent the means ± SEM of 7 independent experiments each. Statistical significance: (a) *GA-treated versus
untreated MO-DCs; (b) *versus unstimulated untreated MO-DCs (*P < 0.05, **P < 0.01).
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highlighted by impaired RelB expression in MO-DCs
treated with GA in the course of stimulation.
GA does not exert cytotoxic effects on resting T cells, but
abrogates their stimulation-induced proliferation
Finally, we investigated whether GA besides its detri-
mental effects on MO-Cs may also directly modulate
T cell activation. Resting T cells were not affected in
their viability upon treatment with GA (Figure 6a). Acti-
vated allogenic MO-DCs induced higher levels of T cell
proliferation than unstimulated MO-DCs (Figure 6b).When GA was added to these cocultures, the proliferative
potential of T cells stimulated by either MO-DC popula-
tion strongly dropped. In this setting, GA may affect T cell
activation/proliferation directly, but also indirectly by inhi-
biting MO-DC functions. Therefore, T cells were also
stimulated in a DC-independent manner by applying T
cell-activating antibodies. Polyclonal stimulation resulted
in a strong T cell proliferative response, which was com-
pletely abrogated in the presence of GA (Figure 6c).
These results indicate that GA may hamper the induction
of adaptive immune responses both on the level of DC acti-
vation as well as T cell stimulation and/or proliferation.
Figure 5 GA affects TF activities, and reduces RelB expression
in MO-DCs. (a) HEK293T cells were transfected with TF responsive
luciferase reporter vectors. After 5 h, cells were split, and aliquots
were differentially treated in triplicates with GA, and/or the MO-DC
maturation cocktail as indicated. One day later, luciferase activities
were detected. Data show the means ± SEM of three experiments,
normalized to the relative luciferase activity of untreated HEK293T
cells, arbitrarily set to 1. Statistical significance: *versus unstimulated
untreated, and #GA-treated at stimulated versus unstimulated state,
and $GA-treated versus untreated at stimulated state (*,$P < 0.05,
**P < 0.01, ***,###P < 0.001). (b) Groups of MO-DCs were generated as
described (see legend of Figure 2). Derived protein (each 30 μg) was
separated on SDS-PAGE, and western blots were performed. β-actin
served as loading control. The graph is representative of two
independent experiments.
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Here we show that the prototypic HSP90 inhibitor GA
exerted cytotoxic effects on human MO-DCs both at
unstimulated state as well during stimulation in a dose-
dependent manner. We chose a concentration of GA
(0.1 μM) devoid of detrimental effects on the viability of
MO-DCs to analyze the influence of this agent on the
immuno-phenotype and functions of MO-DCs. Of note,
this concentration broadly corresponds to plasma levels
of GA-derived HSP90 inhibitors used in the course of
treatment of patients in clinical trials [32,33].
Unstimulated MO-DCs treated with GA were charac-
terized by differential regulation of DC surface markers:
While CD80 expression levels were reduced, HLA-DR,
CD83, and CD86 were upregulated. In accordance with
the elevated expression of the latter markers, whose ex-
pression is controlled in part by NF-κB [14], we noted
moderately enhanced NF-κB activity in GA-treated
HEK293T cells, which may explain in part the enhanced
state of activation of likewise treated MO-DCs. However,
neither the expression level of the endogenous NF-κB
inhibitor IκB-α [34], nor the level and activation state of
the ubiquitously expressed NF-κB family member p65
[35] were altered in GA-treated MO-DCs. Moreover, ex-
pression of the largely APC-restricted NF-κB family
member RelB [36] was actually reduced in this MO-DC
population. Therefore, further analysis is required to elu-
cidate whether GA treatment results in activation of NF-
κB in unstimulated MO-DCs, and which of the other
members of this TF family [13] may be involved. Besides,
the partial activation of GA-treated MO-DCs may also
result at least in part from reduced activity of signaling
pathways and TFs that serve to maintain a low state of
activation in DCs. For example, agents that activate
the cAMP/PKA signaling axis also induce a largely
maturation-resistant DC activation state [37]. In this
regard, we observed moderate down-regulation of
CREB activity in GA-treated HEK293T cells, and it re-
mains to be analyzed whether impaired CREB activity
in turn may favour DC activation.
In striking contrast to our findings of enhanced ex-
pression of some DC activation markers in GA-treated
MO-DCs, Bae and coworkers [38] observed profound
down-regulation of HLA molecules as well as of all cost-
imulators monitored in MO-DCs subjected to treatment
with GA. This discrepancy may be due to GA dose ef-
fects, since Bae and coworkers used a tenfold higher
dose of GA (1 μM) [38] than employed by us, which in
their study was the only dose tested on MO-DCs to as-
sess apoptosis-inducing effects.
Unstimulated DCs are specialized in the uptake of
antigen by various means, including receptor-mediated
endocytosis, but cease to engulf antigen upon stimula-
tion [39]. Both in our study and in the report of Bae and
Figure 6 GA impairs the proliferation of stimulated CD4+
T cells. CD4+ T cells were assayed for effects of GA on their (a)
viability, and (b, c) stimulation-induced proliferation. (a) CD4+ T cells
(5×105) were supplemented with rhIL-2 (20 U/ml), seeded in
triplicates, and aliquots were treated with 0.1 μM GA. After 48 h,
viability was assessed by MTT assay. Viability of untreated cells
was arbitrarily set to 100%. Data represent means ± SEM of two
independent experiments. (b, c) CD4+ T cells (105) were stimulated
(b) by allogenic MO-DCs (2×104) at unstimulated (−) or stimulated
state (stim), and (c) by anti-CD3 (1 μg/ml) plus anti-CD28 antibodies
(0.5 μg/ml). T cell proliferation was determined by incorporation of
[3H] thymidine for the last 16 h of culture. Data represent the
means ± SEM of three independent experiments each. Statistical
significance: (b) *versus unstimulated MO-DCs, $versus stimulated
MO-DCs without GA, (c) *versus unstimulated T cells, $versus
stimulated T cells without GA (**,$$P < 0.01, ***,$$$P < 0.01).
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by slightly decreased endocytotic activity. The finding of
a GA-dependent decrease in antigen uptake by MO-DCs
supports the notion of a partially activated state. Alter-
natively, it is possible that proteins involved in receptor-
mediated endocytosis may constitute genuine HSP90 cli-
ent proteins, affected by GA-mediated HSP90 inhibition.
Interestingly, HSP90 is required for transfer of internal-
ized antigen from the endosome to the cytosol for sub-
sequent cross-presentation [40].
In our study, unstimulated GA-treated DCs displayed
a slightly enhanced allo CD4+ T cell stimulatory capacity.
This finding may be explained in part by the moderately
upregulated expression of HLA-DR and of CD83 as well
as by the tendency of elevated CD86 surface levels in
GA-treated MO-DCs. This may may compensate for the
impaired expression of CD80, in order to facilitate ele-
vated antigen presentation and T cell stimulation.
In marked contrast to the partially stimulatory effects
of GA on unstimulated MO-DCs, this agent interfered
with the stimulation-associated increase in surface ex-
pression of all DC activation markers monitored, as well
as proinflammatory mediators, while HLA-DR remained
largely unaffected. In case of CD80, the only molecule
diminished in expression by GA treatment in unstimu-
lated MO-DCs, GA completely abrogated the otherwise
stimulation-associated increase in surface expression.
This finding suggests that CD80 may be regulated in a
qualitatively distinct manner as compared with the other
markers assessed. Similarly, Bae and coworkers reported
on lower expression of all DC markers monitored for
MO-DCs treated with GA (1 μM) during stimulation
[38]. However, in that study, effects of GA on DC sur-
face marker expression were not assessed side-by-side in
unstimulated and stimulated MO-DCs, given that ex-
pression levels of most activation markers shown were
lower in stimulated than in unstimulated control MO-
DCs. Therefore, it remains unclear whether treatment of
MO-DCs with GA at that high dose abolished stimulation-
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tially inhibited upregulation, as was observed for most mol-
ecules in our work for a ten-fold lower dose of GA applied.
In agreement with impaired upregulation of the cyto-
skeletal protein Fscn1, required for dendrite formation
[22] and migration [41], MO-DCs cotreated with GA in
the course of stimulation were characterized by a lower
migratory activity than the corresponding control group.
This functional defect may reflect in part impaired actin
polymerization, shown to require HSP90 activity [42].
MO-DCs treated with GA during stimulation, in ac-
cordance with reduced upregulation of DC activation
markers and proinflammatory cytokines, exhibited lower
allo CD4+ T cell activation capacity as compared with
stimulated control MO-DCs. Consequently, the corre-
sponding DC/T cell cocultures contained lower levels of
the Th1/Th2 effector cytokines [43] IFN-γ, and IL-5.
In general, stimulation of MO-DCs results in the acti-
vation of a number of signaling pathways, and a number
of key regulators have been reported to constitute client
proteins of HSP90. In this regard, STAT1 has been iden-
tified as a genuine HSP90 target [44]. Here we show that
GA-treated HEK293T cells displayed impaired STAT1/2
activity under basal conditions, and impaired upregula-
tion in response to stimulation. In stimulated DCs,
STAT1 has been demonstrated to mediate increased ex-
pression of activation markers like CD40 [45], and its in-
hibition may contribute to impaired DC maturation.
Moreover, MAPK members JNK [46], and p38 [47]
have been shown to positively regulate DC activation,
and both kinases interact with HSP90 (JNK [48], p38
[49]). Both MAPK are known to activate PKC, which in
turn mediates phosphorylation-dependent activation of
TFs of the AP-1 family that are important i.e. for expres-
sion of MMP-9 in stimulated DCs as a prerequisite for
emigration from the periphery [50]. In line with the rele-
vance of HSP90-mediated protein maturation of either
MAPK, we observed impaired upregulation of AP-1 ac-
tivity in HEK293T cells cotreated with GA and the mat-
uration cocktail. Besides, stimulation-dependent MAPK
activation is known increase of NF-κB activity [13],
based on transient degradation of the endogenous inhibi-
tor IκB-α [34], and in case of APCs also on elevated ex-
pression and activity of the NF-κB family member RelB
[51]. In case of DCs, RelB is essential for stimulation-
dependent increases of activation marker expression and
consequently the T cell stimulatory capacity [33]. There-
fore, our finding of GA-dependently impaired RelB ex-
pression in stimulated Mo-DCs may explain in part
the detrimental effects of this agent on the phenotype
and function of stimulated Mo-DCs. In HEK293T cells,
GA-treatment mediated no detrimental effect on the
stimulation-associated increase in NF-κB activity,
which may be explained by the APC-specific characterof RelB expression [51]. However, in previous studies
inhibition of HSP90 by GA was shown to diminish NF-
κB activity in tumor cells due to impaired expression
of the NK-κB signaling regulators IKK [15], NIK [16],
and RIP1 [17]. Limited activity of either regulator may
contribute to attenuated RelB expression in stimulated
MO-DCs cotreated with GA.
In T cells GA may inhibit the expression of the tyro-
sine kinase lck, and impair its stimulation-induced phos-
phorylation as evidenced in a human T cell line (Jurkat)
[52,53]. Due to this early block in T cell activation, IL-2
production of stimulated T cells was largely abrogated.
Most recently, GA was demonstrated to affect as well
the expression of several T cell receptor-associated mol-
ecules, namely TCRαß, CD4 and CD28 [54]. In accord-
ance, GA prevented the proliferation of lymphocytes
treated with stimulatory antibodies [53] and of T cells
stimulated by either MO-DCs or mitogen [54]. In line, we
observed largely abrogated proliferation of CD4+ T cells
stimulated by unstimulated or stimulated MO-DCs or by
application of stimulatory antibodies.
Conclusions
Our study has shown that GA-mediated inhibition of
HSP90 in unstimulated MO-DCs may result in partial
activation of the cells by yet unknown mechanisms. On
the other hand, GA treatment impaired MO-DC stimu-
lation and largely abrogated both polyclonal and DC-
mediated T cell proliferation. Chemotherapeutics that
act to inhibit HSP90 may therefore exert rather inhibi-
tory effects on the patients’ immune system, and most
likely are not preferable for combination with immuno-
therapy that targets the DC/T cell axis to mount potent
anti-tumor responses.
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